Skip to content

Effect of Prior Atorvastatin Treatment on the Frequency of Hospital acquired Pneumonia and Evolution of Biomarkers in Patients with Acute Ischemic Stroke

Effect of Prior Atorvastatin Treatment on the Frequency of Hospital acquired Pneumonia and Evolution of Biomarkers in Patients with Acute Ischemic Stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ROC-17010633
Enrollment
Unknown
Registered
2017-02-15
Start date
2008-01-20
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hospital acquired Pneumonia

Interventions

prior atorvastatin treatment group:prior atorvastatin treatment
compare group:none

Sponsors

Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients were eligible for enrolment if they were diagnosed with acute ischemic stroke by magnetic resonance imaging (MRI); aged between 18 and 80 years; Glasgow Coma Scale (GCS) = 8;

Exclusion criteria

Exclusion criteria: Patients were excluded from the study if they were moribund or not expected to survive 28 days because of an underlying irreversible medical condition; had active pneumonia when admitted to ICU or had extrapulmonary infection during ICU stay; had a known intolerance to statins or were unable to have enteral administration of statin; had severe liver disease (acute liver failure or chronic liver disease with Child-Pugh classification C); had a serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level greater than three times the normal value or a serum creatinine kinase (CK) level greater than five times the upper limit of normal levels; had commenced statin therapy less than 4 weeks before hospital admission or had statin stopped for more than 72 hours before the development of ischemic stroke; were pregnant or if informed consent could not be obtained.

Design outcomes

Primary

MeasureTime frame
incidence of HAP;incidence of VAP;

Countries

China

Contacts

Public ContactYu Yuetian

Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

fishyyt@sina.com+86 13818227011

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 27, 2026